Effects of adiponectin on osteoclastogenesis from mouse bone marrow-derived monocytes

Wu,Xia; Huang,Leitao; Liu,Jichun

doi:10.3892/etm.2018.7069

Effects of adiponectin on osteoclastogenesis from mouse bone marrow-derived monocytes

Authors:
- Xia Wu
- Leitao Huang
- Jichun Liu
View Affiliations

Affiliations: Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: December 7, 2018 https://doi.org/10.3892/etm.2018.7069
Pages: 1228-1233
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of adiponectin on bone marrow‑derived monocytes (BMMs) in the process of osteoclastogenesis. Primary BMMs derived from the mouse bone marrow were cultured, which were then treated with different concentrations of adiponectin and macrophage colony stimulating factor (M‑CSF). Cell viability was determined by measuring the absorbance after 24 h with Cell Counting Kit‑8 reagent. BMM cells treated with adiponectin and receptor activator of nuclear factor‑κB ligand (RANKL) were induced and differentiated to mature osteoclasts for 1 week, and then stained with tartrate‑resistant acid phosphatase (TRAP). The number of osteoclasts was evaluated under light microscopy. The expression of adiponectin in BMMs at the gene and protein levels was further assessed with reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. The cellular proliferation experiment demonstrated that the optical density value decreased gradually with an increase of adiponectin concentration, with statistically significant differences detected among groups. In addition, the number of osteoclasts in the adiponectin‑treated group was significantly reduced compared with that in the control group. Adiponectin expression was confirmed in BMMs at both the protein and mRNA levels. In conclusion, the present data demonstrated that adiponectin has a significant inhibitory effect on the osteoclast differentiation and proliferation of BMMs, suggesting a novel strategy for preventing osteoporosis.

View Figures

View References

1	Vats A, Tolley NS, Polak JM and Buttery LD: Stem cells: Sources and applications. Clin Otolaryngol Allied Sci. 27:227–232. 2002. View Article : Google Scholar : PubMed/NCBI
2	Poudyal H and Brown L: Osteoporosis and its association with non-gonadal hormones involved in hypertension, adiposity and hyperglycaemia. Curr Drug Targets. 14:1694–1706. 2013. View Article : Google Scholar : PubMed/NCBI
3	Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 94:646–650. 1993. View Article : Google Scholar : PubMed/NCBI
4	NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA. 285:785–795. 2001. View Article : Google Scholar : PubMed/NCBI
5	Harvey N, Dennison E and Cooper C: Osteoporosis: Impact on health and economics. Nat Rev Rheumatol. 6:99–105. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA and Cooper C: IOF Working Group on Epidemiology and Quality of Life: A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 23:2239–2256. 2012. View Article : Google Scholar : PubMed/NCBI
7	Melton LJ III, Chrischilles EA, Cooper C, Lane AW and Riggs BL: Perspective. How many women have osteoporosis? J Bone Miner Res. 7:1005–1010. 1992.PubMed/NCBI
8	South-Paul JE: Osteoporosis: Part I. Evaluation and assessment. Am Fam Physician. 63:897–904, 908. 2001.PubMed/NCBI
9	Kanazawa I: Adiponectin in metabolic bone disease. Curr Med Chem. 19:5481–5492. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 277:25863–25866. 2002. View Article : Google Scholar : PubMed/NCBI
11	Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 8:1288–1295. 2002. View Article : Google Scholar : PubMed/NCBI
12	Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20:1595–1599. 2000. View Article : Google Scholar : PubMed/NCBI
13	Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD and Liao EY: Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 21:1648–1656. 2006. View Article : Google Scholar : PubMed/NCBI
14	Jürimäe J and Jürimäe T: Plasma adiponectin concentration in healthy pre- and postmenopausal women: Relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab. 293:E42–E47. 2007. View Article : Google Scholar : PubMed/NCBI
15	Lewiecki EM: RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther. 6:1041–1050. 2006. View Article : Google Scholar : PubMed/NCBI
16	Schett G, Hayer S, Zwerina J, Redlich K and Smolen JS: Mechanisms of Disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 1:47–54. 2005. View Article : Google Scholar : PubMed/NCBI
17	Szulc P and Delmas PD: Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 19:1683–1704. 2008. View Article : Google Scholar : PubMed/NCBI
18	Yamauchi T and Kadowaki T: Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes. 32 Suppl 7:S13–S18. 2008. View Article : Google Scholar
19	Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, et al: Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem. 99:196–208. 2006. View Article : Google Scholar : PubMed/NCBI
20	Belaaouaj A, Kim KS and Shapiro SD: Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. Science. 289:1185–1188. 2000. View Article : Google Scholar : PubMed/NCBI
21	Adkison AM, Raptis SZ, Kelley DG and Pham CT: Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest. 109:363–371. 2002. View Article : Google Scholar : PubMed/NCBI
22	Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW and Roes J: Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity. 12:201–210. 2000. View Article : Google Scholar : PubMed/NCBI
23	Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, et al: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 102:1296–1301. 2000. View Article : Google Scholar : PubMed/NCBI
24	Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, Hanazawa S and Yamashita Y: Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 579:6821–6826. 2005. View Article : Google Scholar : PubMed/NCBI
25	Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, et al: Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 428:758–763. 2004. View Article : Google Scholar : PubMed/NCBI
26	Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, et al: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 145:527–538. 1999. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wei X, Li G, Yang X, Ba K, Fu Y, Fu N, Cai X, Li G, Chen Q, Wang M, et al: Effects of bone morphogenetic protein-4 (BMP-4) on adipocyte differentiation from mouse adipose-derived stem cells. Cell Prolif. 46:416–424. 2013. View Article : Google Scholar : PubMed/NCBI
29	Chambers TJ: Regulation of the differentiation and function of osteoclasts. J Pathol. 192:4–13. 2000. View Article : Google Scholar : PubMed/NCBI
30	Glantschnig H, Fisher JE, Wesolowski G, Rodan GA and Reszka AA: M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10:1165–1177. 2003. View Article : Google Scholar : PubMed/NCBI
31	Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y and Yeung YG: Biology and action of colony - stimulating factor-1. Mol Reprod Dev. 46:4–10. 1997. View Article : Google Scholar : PubMed/NCBI
32	Wang QP, Li XP, Wang M, Zhao LL, Li H, Xie H and Lu ZY: Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: An in vivo study. Endocrine. 47:845–853. 2014. View Article : Google Scholar : PubMed/NCBI
33	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
34	Yamaguchi N, Kukita T, Li YJ, Kamio N, Fukumoto S, Nonaka K, Ninomiya Y, Hanazawa S and Yamashita Y: Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett. 582:451–456. 2008. View Article : Google Scholar : PubMed/NCBI
35	Abu-Amer Y: NF-κB signaling and bone resorption. Osteoporos Int. 24:2377–2386. 2013. View Article : Google Scholar : PubMed/NCBI
36	Dimitri P and Rosen C: The central nervous system and bone metabolism: An Evolving Story. Calcif Tissue Int. 100:476–485. 2017. View Article : Google Scholar : PubMed/NCBI